Carmustine Articles
Japan stock market week to April 13, 2009
14 April 2009
Eisai licenses Gliadel Wafer to Nobelpharma
7 April 2009
Positive data on MGI Pharma's Gliadel
28 January 2008
MGI's 4th-qtr 2006 net loss narrows to $19.6M
19 February 2007
MGI Pharma moves into loss for 2nd-qtr
24 July 2006
ECJ ruling on SPCs "bad news" for pharma
15 May 2006
UK's NICE poised to reject Gliadel Implant
27 February 2006
ECoJ SPC Opinion a boost for biopharma
5 December 2005
UPDATE: MGI Pharma makes $178M bid for Guilford, plus assuming $69.4M convertible debt
1 August 2005
Guilford loses 20% of workforce over Gliadel
6 June 2005
Guilford's Gliadel gets Orphan Drug status
4 October 2004
Guilford's Gliadel OKed for new use in EU
20 September 2004
Guilford Pharma sees huge rise in 2nd-qtr loss
16 August 2004
Guilford reduces losses slightly
23 February 2004
Guilford Pharmaceuticals narrows losses in second quarter
18 August 2003
Guilford Pharma sales decline, losses creep up
24 February 2003
Guilford posts $16.8M loss in 2nd quarter
19 August 2002
Guilford's loss down
20 May 2002
DTI-015 granted Orphan Drug
29 April 2002
Guilford hit as FDA says no to new Gliadel use
1 April 2002
Guilford sees Gliadel unit sales up 42%
25 February 2002
Guilford seeking EU expanded Gliadel use
11 February 2002
Guilford results impress
8 November 2001
Date set for FDA review of Gliadel Wafer
12 October 2001
FDA reschedules Gliadel Wafer review
13 September 2001
FDA's ODAC to review Gliadel, Zevalin
4 September 2001
Guilford placement raises $59 million
13 June 2001
FDA accepts Gliadel Wafer sNDA for review
8 June 2001
New test predicts response to cancer treatment
7 November 2000
Direct Therapeutics gains orphan drug status for DTI-015
10 August 2000
Guilford sees progress across R&D programs
4 November 1999
Gliadel gains positive opinion in France
1 July 1999
Sugen Starts SU101 Phase II Trials
22 September 1998
Pacific Phase I Brain Tumor Trials at Duke
22 September 1998
Oncology News In Brief
4 March 1998
Guilford Goes Into Profit
17 March 1997
First Launch Of Gliadel Implant For Brain Tumors
3 March 1997
R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr
4 November 1996
US Quarterly Results Show Improvements
4 November 1996
FDA Clears Gliadel For Brain Cancer
30 September 1996
NEW YORK STOCK COMMENT
30 September 1996
Guilford To Seek Broad Use For Gliadel
8 July 1996
Guilford's Gliadel Reviewed
8 April 1996
Guilford Files For Brain Cancer Treatment
12 February 1996
Many US Biotech Firms See Good 3rd Qtr Sales Growth
13 November 1995
Sandoz MDR Drug Shows Promise In Early Trials
13 November 1995
Treatment IND Approved For Gliadel
6 November 1995
SCIOS NOVA FORMS CNS SUBSIDIARY
11 October 1993
Showing 1-53 of 53 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
